logo

Immunitybio, Inc. (IBRX)



Trade IBRX now with
  Date
  Headline
4/29/2021 9:17:28 AM ImmunityBio Launches Phase 2 Trial Of IL-15 Superagonist Anktiva With Antiretroviral Therapy To Inhibit HIV Reservoirs
2/16/2021 9:11:08 AM ImmunityBio Announces Presentation Of Phase 2/3 Trial Results Of BCG Unresponsive Non-Muscle Invasive Bladder Cancer
1/28/2021 9:12:39 AM ImmunityBio Reports Positive Phase 2 Results Showing That Anktiva Restores Activity Of Checkpoint Inhibitors In Patients
12/21/2020 6:12:23 AM ImmunityBio Announces Primary Endpoint Met Of Pivotal Phase 2/3 Trial
12/21/2020 6:08:27 AM ImmunityBio And NantKwest Enter Agreement To Merge In Stock-for-stock Transaction
12/10/2020 11:06:04 PM ImmunityBio's HAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection Of Airways In Non-Human Primates
11/23/2020 9:12:34 AM ImmunityBio : Preclinical Data Shows IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
10/21/2020 5:16:43 PM ImmunityBio And NantKwest Announce First Patient Dosed In Phase 1 Clinical Trial Of HAd5-COVID-19
10/15/2020 6:03:25 AM ImmunityBio: FDA Authorizes To Begin Phase I Clinical Trial Of HAd5-COVID-19
9/10/2020 9:14:33 AM Brink Biologics Announces License Agreement With Fresenius Kabi SwissBioSim GmbH